secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-10-10T23:59:59+00:00
Accession:  0001437749-25-030816
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences reports 94% PVI success at 3 months in nPulse cardiac study
-----------------------------------------------------------------------------

- All (100%) posterior box isolations acutely successful in high-dose cohort; 94% PVI success per vein at ~3 months.
- Average total ablation time of 50 seconds with 13 applications; no esophageal or phrenic nerve damage reported.
- No ablation-related severe or major adverse events in 44 treated patients across three European sites.
- CEO confirms on track to initiate IDE study this year for nPulse Cardiac Surgical System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925030816/0001437749-25-030816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925030816/plse20251009_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-030816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer